Developing treatments for COVID-19

S49 C-reactive protein as a biomarker for improved efficacy of lenzilumab in Covid-19 patients: results from the LIVE-AIR trial

Pub Date : 2021-11-01 DOI: 10.1136/thorax-2021-btsabstracts.55 Z. Temesgen, C. Burger, J. Baker, C. Polk, C. Libertin, C. Kelley, VC Marconi, R. Orenstein, VM Catterson, W. Aronstein, C. Durrant, D. Chappell, O. Ahmed, G. Chappell, A. Badley

S53 Impact of empirical antibiotic use in patients with COVID-19 on morbidity and mortality during the first and second UK SARS-CoV-2 waves

Pub Date : 2021-11-01 DOI: 10.1136/thorax-2021-btsabstracts.59 S. Waring, G. Gamtkitsulashvili, S. Kumar, Y. Narayan, A. D'Souza, S. Jiwani, O. Taylor, G. Collins, K. Patrick, A. Sethuraman, S. Naik, S. Kuckreja, R. Ragatha, M. Anwar, U. Ekeowa, P. Russell

S50 A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial

Pub Date : 2021-11-01 DOI: 10.1136/thorax-2021-btsabstracts.56 T. Hinks, L. Cureton, R. Knight, A. Wang, J. Cane, VS Barber, J. Black, SJ Dutton, J. Melhorn, M. Jabeen, P. Moss, R. Garlapati, T. Baron, G. Johnson, F. Cantle, D. Clarke, S. Elkhodair, J. Underwood, D. Lasserson, I. Pavord, SB Morgan, D. Richards